单极纺锤体1激酶抑制剂S81694静脉给药在晚期转移性实体瘤成人患者中的首次人体、首创Ⅰ期研究
S81694是单极纺锤体1激酶抑制剂。CL1-81694-001为首次人体研究,采用患者间剂量递增,在≥3例患者的队列中评估单药S81694的安全性、耐受性、剂量限制性毒性(DLT)、最大耐受剂量(MTD)和推荐Ⅱ期剂量(RP2D),给药方案为28天周期第1、8、15天1小时静脉输注。38例患者接受4至135 mg/m2/周剂量治疗,未达到MTD,因申办方决定提前终止入组而未定义RP2D。
要点
- 38例患者接受4至135 mg/m2/周剂量治疗,共144个周期,中位2周期/患者(范围1-32周期)。
- 常见治疗中出现的不良事件为疲乏(22例;57.9%)、贫血(17例;44.7%)和恶心(12例;31.6%)。
- 因申办方决定提前终止入组,未达到MTD;因优先开发S81694与细胞毒药物联合方案,未定义RP2D。
核心结论
- S81694可作为单药在实体瘤成人患者中安全给药,方案为28天周期第1、8、15天给药,剂量至135 mg/m2/周未达到MTD。
- 因优先开发S81694与细胞毒药物联合方案(基于新出现的临床前数据),未定义RP2D。
研究设计与样本
- CL1-81694-001为首次人体研究,采用单药S81694患者间剂量递增,在≥3例患者的队列中评估安全性和耐受性,确定DLT、MTD和RP2D。
- 给药方案为28天周期第1、8、15天1小时静脉输注。
- 共38例患者接受治疗,剂量范围4至135 mg/m2/周;共给药144个周期(中位2周期/患者;范围1-32周期)。
主要发现
- 患者因疾病进展(78.9%)、不良事件(AE;18.4%)或撤回知情同意(2.6%)停止治疗。
- 22例患者(57.9%;49个周期)进行了治疗调整。
- 常见治疗中出现的不良事件为疲乏(22例;57.9%)、贫血(17例;44.7%)和恶心(12例;31.6%)。
- 血液学毒性较轻,3例患者观察到3级贫血,中性粒细胞减少主要见于135 mg/m2剂量水平。
- 3例第一周期DLT包括G3贫血(4 mg/m2剂量)、G4高血压(20 mg/m2)、G3疲乏(135 mg/m2)。
关键数值与推荐
- MTD未达到,原因为基于申办方决定提前终止入组。
- RP2D未定义,原因为优先开发S81694与细胞毒药物联合方案(基于新出现的临床前数据)。
- DLT包括G3贫血(4 mg/m2剂量)、G4高血压(20 mg/m2剂量)、G3疲乏(135 mg/m2剂量)。
临床怎么用
- 原文未据此给出推荐。
局限性
- MTD未达到,原因为基于申办方决定提前终止入组。
- RP2D未定义,原因为优先开发S81694与细胞毒药物联合方案(基于新出现的临床前数据)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: S81694 is an inhibitor of monopolar spindle 1 kinase, a target expressed in proliferating cells. CL1-81694-001 was the first-in-human study aiming at identifying a safe dosing schedule in solid tumour patients. PATIENTS AND METHODS: This trial was based on inter-individual dose-escalation of single agent S81694 in cohorts of ≥3 patients to assess the safety and tolerability and determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and recommended phase II dose (RP2D), with S81694 given on days 1,8,15 of a 28-day cycle as 1-h infusion. RESULTS: 38 patients were treated at doses ranging from 4 to 135 mg/m2/week; 144 cycles were administered (median 2/patient; range 1-32 cycles). Patients discontinued treatment for disease progression (78.9%), adverse events (AE; 18.4%) or withdrawal of consent (2.6%). Treatment modifications occurred in 22 patients (57.9%; 49 cycles). Common treatment-emergent AEs were fatigue (22 patients;57.9%), anaemia (17;44.7%) and nausea (12;31.6%). Haematological toxicity was mild, with Grade 3 anaemia observed in three patients and neutropenia mainly seen at the 135 mg/m2 dose level. Three first cycle DLTs included G3 anaemia (4 mg/m2 dose), G4 hypertension (20 mg/m2), G3 fatigue (135 mg/m2). MTD was not reached due to premature discontinuation of enrolment based on a sponsor decision. Among 35 patients evaluable for response, one (renal cell carcinoma) had a complete response, one (hepatocellular carcinoma) had a transient decrease of target lesions and 13 had stable disease. Seven patients remained on study for ≥6 cycles, two at the 135 mg/m2 dose. CONCLUSIONS: S81694 can be administered safely as a single agent in adults with solid tumours on days 1,8,15 of a 28-day cycle up to a dose of 135 mg/m2/week without reaching MTD. The RP2D was not defined due to the prioritization of the use of S81694 in combination with cytotoxic agents, based on emerging preclinical data. TRIAL REGISTRATION: EudraCT number: 2014-002023-10; ISRCTN registry ISRCTN35641359.
引用
- Schöffski P, Awada A, de la Bigne AM, et al. First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours. Eur J Cancer. 2022. PMID: 35567919. doi:10.1016/j.ejca.2022.04.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。